How Yubo Achieved Profitability By Breaking Social Media's Ad Addiction
Yubo CEO and co-founder Sacha Lazimi: "The goal is to create authentic and meaningful new connections that are not based on followers or likes or comments."
Related
MSInsight : Paving the Path towards Precision Oncology
CEO and co-founder Arnaud Dr. Cutivet: “MSI cancer cells are present in 4% of cancers, especially colorectal, stomach, and endometrial cancers. Early detection, particularly in colorectal cancer, means we can use immunotherapy effectively, potentially saving lives.”
Descartes Underwriting: Doubling Down On Climate Risk As Insurance Industry Retreats
Chief Science Officer Kévin Dedieu: "AI represents between 2-5% of our tech investments. Next year, we’re increasing that by 10%, with more resources dedicated to AI and using it for our core models. The cost of AI is relatively low, but its impact is huge.”
Spore.Bio's AI Slices Bacteria Testing From Days to Minutes
The startup has raised $31.3 million for its light-based AI technology to disrupt centuries-old testing methods across food, pharma, and cosmetics industries.
How WeWard Convinced Venus Williams To Put Her Money Where Your Feet Are
CEO Yves Benchimol: "She definitely understood how a startup works. She said, 'Okay, I want to be a shareholder of this company. I trust it in terms of its image and business. It can be huge, especially in the US and in terms of impact.'"
Latest
🤖 La Machine #24: Inside FlexAI's Ambitions 🤖
Pigment launches AI agents; Aldebaran Robotics folds; Eurazeo bets on infrastructure.
FlexAI: Pioneering Universal AI Compute Infrastructure
Modern AI workloads were being forced to run on computing architectures designed decades ago. FlexAI wants to create a faster, more flexible system that enables rapid scaling.
🇫🇷 French Tech Wire: Oh, Good Grief! The Great Funding Famine Deepens
VC funding remains in freefall as French startups go hungry; MSInsight offers hope to the future of cancer detection; Yubo offers hope to companies that want to be profitable.
MSInsight : Paving the Path towards Precision Oncology
CEO and co-founder Arnaud Dr. Cutivet: “MSI cancer cells are present in 4% of cancers, especially colorectal, stomach, and endometrial cancers. Early detection, particularly in colorectal cancer, means we can use immunotherapy effectively, potentially saving lives.”